Muvon Therapeutics has linked its cell therapy to a 60% drop in stress incontinence episode frequency in a small phase 2 trial, leading the biotech to pitch the candidate as a way to reduce reliance ...
The MarketWatch News Department was not involved in the creation of this content. Zurich, Switzerland, December 03, 2025 -- MUVON Therapeutics AG, a clinical-stage biotechnology company, reports ...
Zurich, Switzerland, December 18, 2025 – MUVON Therapeutics, a clinical-stage biotechnology company focused on developing a novel platform for the regeneration of skeletal muscle tissue, announces the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback